Immunoglobulin
Sponsors
Sato Yoshiaki, National Eye Institute (NEI), Instituto Grifols, S.A., Brigham and Women's Hospital, Assistance Publique - Hôpitaux de Paris
Conditions
Alzheimer's DiseaseAntibody-mediated RejectionCIDP - Chronic Inflammatory Demyelinating PolyneuropathyHumoral RejectionImmuoglobulinKawasaki DiseaseKawasaki Disease
Kawasaki diseaseOptic Neuritis
Phase 2
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
CompletedNCT01561053
Start: 2012-04-19End: 2018-03-06Updated: 2019-07-31
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
TerminatedNCT01895127
Start: 2013-11-30End: 2016-04-30Updated: 2017-09-21
Immunotherapy and Paraneoplastic Neurological Syndromes
CompletedNCT02343211
Start: 2013-11-30End: 2016-12-31Target: 17Updated: 2017-11-06
Phase 3
Intravenous Immunoglobulin Therapy in Optic Neuritis
CompletedNCT00000117
Start: 1995-08-31End: 1997-12-31Updated: 2009-09-17
A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)
NCT03200561
Start: 2013-10-17End: 2020-12-31Target: 100Updated: 2017-06-27
Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency
WithdrawnNCT03492710
Start: 2019-04-30End: 2019-04-30Updated: 2020-07-07
Randomised Evaluation of COVID-19 Therapy
RecruitingNCT04381936
Start: 2020-03-19End: 2036-06-30Target: 70000Updated: 2024-01-05
Phase 4
Unknown Phase
Related Papers
24 more papers not shown